Treatment for Legionnaires' disease. Macrolides or quinolones?;Tratamiento de la neumonía por Legionella pneumophila. ¿Macrolidos o quinolonas?

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 24, Issue 6, 2006, Pages 360-364

  Falcó, Vicenç ^a   Molina, Israel ^a   Juste, Concha ^a   Crespo, Manel ^a   Almirante, Benito ^a   Pigrau, Carles ^a   Ferrer, Adelaida ^a   Bravo, Carlos ^a   Palomar, Mercedes ^a   Pahissa, Albert ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Azithromycin; Legionella pneumophila pneumonia; Levofloxacin; Macrolides

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; LEVOFLOXACIN; MACROLIDE; QUINOLONE DERIVATIVE;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FEVER; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; LEGIONELLA PNEUMOPHILA; LEGIONNAIRE DISEASE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PNEUMONIA; PROSPECTIVE STUDY; RISK FACTOR; SPAIN;

EID: 33746536107     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13089688     Document Type: Article

References (23)

1. Benin AL, Benson RF, Besser RE. Trends in legionnaires disease, 1980-1998: declining mortality and new patterns of diagnosis. Clin Infect Dis. 2002;35:1039-46.
2. Jericó C, Nogués X, Santos J, Félez M, Garcés JM, Mariñosa M, et al. Brote epidémico de neumonía comunitaria por Legionella pneumophila en Barcelona: "el brote de la Barceloneta". Efecto del diagnóstico y tratamiento precoz. Rev Clin Esp. 2004;204:70-4.
3. Pahissa A, Falcó V. Legionella pneumophila: un problema sanitario de permanente actualidad. Rev Clin Esp. 2004;204:61-3.
4. Sabriá M. Legionella pneumophila serogrupo 1. Enferm Infecc Microbiol Clin. 2003;21:391-3.
5. Blázquez Garrido RM, Espinosa Parra FJ, Alemany Frances L, Ramos Guevara RM, Sánchez-Nieto JM, Segovia Hernández M, et al. Antimicrobial chemotherapy for legionnaires disease: levofloxacin versus macrolides. Clin Infect Dis. 2005;40:800-6.
6. Amsden GW. Treatment of legionnaires' disease. Drugs. 2005;65:605-14.
7. Stout JE, Yu VL. Legionellosis. N Engl J Med. 1997;337:682-7.
8. Stout JE, Sens K, Mietzner S, Obman A, Yu VL. Comparative activity of quinolones, macrolides and ketolides against Legionella species using in vitro broth dilution and intracellular susceptibility testing. Int J Antimicrob Agents. 2005;25:302-7.
9. Plouffe JF, Breiman RF, Fields BS, Herbert M, Inverso J, Knirsch C, et al. Azithromycin in the treatment of Legionella pneumonia requiring hospitalization. Clin Infect Dis. 2003;37:1475-80.
10. Kuzman I, Soldo I, Schonwald S, Culig J. Azithromycin for treatment of community acquired pneumonia caused by Legionella pneumophila: a retrospective study. Scand J Infect Dis. 1995;27:503-5.
11. Fernández N, Gudiol F, Domínguez J, Ausina V, Sopena N. Legionelosis. Clínica, diagnóstico y tratamiento. Med Clin (Barc) 2002;119 Supl 2:29-32.
12. Baltch AL, Bopp LH, Smith RP, Michelsen PB, Ritz WJ. Antibacterial activities of gemifloxacin, levofloxacin, gatifloxacin, moxifloxacin and erythromycin against intracellular Legionella pneumophila and Legionella micdadei in human monocytes. J Antimicrob Chemother. 2005; [Epub ahead of print].
13. Baltch AL, Smith RP, Franke MA, Michelsen PB. Antibacterial effects of levofloxacin, erythromycin, and rifampin in a human monocyte system against Legionella pneumophila. Antimicrob Agents Chemother. 1998;42:3153-6.
14. Mykietiuk A, Carratalá J, Fernández-Sabe N, Dorca J, Verdaguer R, Manresa F, et al. Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy. Clin Infect Dis. 2005;40:794-9.
15. Sabriá M, Pedro-Botet ML, Gómez J, Roig J, Vilaseca B, Sopena N, et al. Fluorquinolones vs macrolides in the treatment of Legionnaires disease. Chest. 2005;128:1401-5.
16. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DA, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243-50.
17. Falcó V, Fernández de Sevilla T, Alegre J, Ferrer A, Martínez Vázquez JM. Legionella pneumophila. A cause of severe community-acquired pneumonia. Chest. 1991;100:1007-11.
18. Gacouin A, Le Tulzo Y, Lavoue S, Camus C, Hoff J, Bassen R, et al. Severe pneumonia due to Legionella pneumophila: prognostic factors, impact of delayed appropriate antimicrobial therapy. Intensive Care Med. 2002;28:686-91.
19. Heath CH, Grove DI, Looke DF. Delay in appropriate therapy of Legionella pneumonia associated with increased mortality. Eur J Clin Microbiol Infect Dis. 1996;15:286-90.
20. Carbon C, Nusrat R. Efficacy of telithromycin in community-acquired pneumonia caused by Legionella pneumophila. Eur J Clin Microbiol Infect Dis. 2004;23:650-2.
21. Howden BP, Stuart RL, Tallis G, Bailey M, Johnson PD. Treatment and outcome of 104 hospitalized patients with legionnaires' disease. Intern Med J. 2003;33:484-8.
22. Yu VL, Greenberg RN, Zadeikis N, Stout JE, Khashab MM, Olson WH, et al. Levofloxacin efficacy in the treatment of community-acquired legionellosis. Chest. 2004;125:2135-9.
23. Roig J, Rello J. Legionna ires' disease: a rational approach to therapy. J Antimicrob Chemother. 2003;51:1119-29.